9th CAR-TCR Summit

Kongressthemen
The commercial success of cell therapies is continuing to grow! With a recent TIL approval, a shift to earlier line CAR-T treatment, and further approvals set for this year, 2024 will be pivotal to demonstrate the clinical benefit of cell therapies and advance breakthroughs in solid tumors and autoimmunity.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/2431289-3?pid=4832

Speakers: Carl June, Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, University of Pennsylvania, and more

https://go.evvnt.com/2431289-2?pid=4832

Frau Ellie Saunders